OTI Selected for Two European Innovation Forums

Massachusetts, USA [July 17th 2026]. The presentation will highlight OTI’s development of OTI-2024, a first-in-class, pathway-based tissue rejuvenation therapy designed to repair pressure-sensor functionality, normalize intraocular pressure, and potentially enable a sustained treatment-free period for patients with glaucoma.

• Date: Thursday, September 10, 2026, 
• Location: Glaziers Hall in London (in person)
• Presenter: Dr. Tina Guanting Qiu, CEO/Founder

OTI was selected from more than 40 emerging-company applicants to present at iNovation® ESCRS 2026, one of the largest European Ophthalmology Conferences.

Tina Guanting Qiu, MD, PhD, Founder and CEO of OTI, will present during Session 7: “Interventional Glaucoma in the Cataract Practice.”

• Date: Friday, September 11, 2026
• Time: 14:29 CEST
• Location: ICC Auditorium, ExCeL London (in person)
• Presenter: Tina Guanting Qiu, MD, PhD, CEO/Founder

The conference bring together leaders from ophthalmology, industry, investment, and medical innovation to discuss emerging technologies and the future of eye care.

“We are honored to present OTI’s glaucoma innovation at both the Ophthalmology Futures European Forum and iNovation ESCRS,” said Dr. Qiu. “These events provide important opportunities to connect with ophthalmology industry leaders and introduce a new treatment paradigm focused on restoring the eye’s natural pressure-regulating function—not merely lowering intraocular pressure.”

Ophthalmology Futures: https://www.ophthalmology-futures.com

iNovation at ESCRS: https://inovation.escrs.org

Massachusetts, USA [July 6th 2026]. OTI’s second PCT application entered the national and regional phases in six major jurisdictions, expanding global patent protection for its trabodenoson MMP therapeutic platform.

Ophthalmic Therapeutic Innovation, Inc. (OTI) announced that its second Patent Cooperation Treaty application, PCT/US2024/012760, entered the national and regional phases in six major jurisdictions between April and June 2026: the United States, Europe, Canada, Australia, China, and Japan.

Titled “Compositions and Methods for Treating Neural Degeneration in Glaucoma and Related Conditions,” the patent application names Guanting Tina Qiu as the inventor.

The application seeks broad intellectual property protection for trabodenoson as a novel matrix metalloproteinase (MMP) therapeutic agent for IOP normalization in treating neural degeneration associated with glaucoma and related conditions. It further supports OTI’s development of a new disease-modifying treatment paradigm extending beyond conventional intraocular pressure reduction.

“This international filing milestone strengthens OTI’s global intellectual property position for trabodenoson as an MMP-based therapeutic,” said Tina Guanting Qiu, MD, PhD, Founder and CEO of OTI. “Our platform is designed to address the underlying tissue and neural degeneration associated with glaucoma, with potential applications extending beyond glaucoma.”

OTI’s first PCT patent family is also progressing through examination in jurisdictions within and outside the United States, further strengthening the company’s global intellectual property portfolio supporting its tissue-rejuvenation and pressure-sensor restoration platform.

OTI has engaged Katie Rubino, IP Partner at Wiggins & Dana LLP to represent company's

patent portfolio (https://www.wiggin.com).